MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 80; no. 9; pp. 1861 - 1874
• Main Authors: Judge, Sarah M, Deyhle, Michael R, Neyroud, Daria, Nosacka, Rachel L, D'Lugos, Andrew C, Cameron, Miles E, Vohra, Ravneet S, Smuder, Ashley J, Roberts, Brandon M, Callaway, Chandler S, Underwood, Patrick W, Chrzanowski, Stephen M, Batra, Abhinandan, Murphy, Meghan E, Heaven, Jonathan D, Walter, Glenn A, Trevino, Jose G, Judge, Andrew R
• Format: Journal Article
• Language: English
• Published: United States 01.05.2020
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-19-1558

Skeletal muscle wasting is a devastating consequence of cancer that contributes to increased complications and poor survival, but is not well understood at the molecular level. Herein, we investigated the role of Myocilin (Myoc), a skeletal muscle hypertrophy-promoting protein that we showed is downregulated in multiple mouse models of cancer cachexia. Loss of Myoc alone was sufficient to induce phenotypes identified in mouse models of cancer cachexia, including muscle fiber atrophy, sarcolemmal fragility, and impaired muscle regeneration. By 18 months of age, mice deficient in Myoc showed significant skeletal muscle remodeling, characterized by increased fat and collagen deposition compared with wild-type mice, thus also supporting Myoc as a regulator of muscle quality. In cancer cachexia models, maintaining skeletal muscle expression of Myoc significantly attenuated muscle loss, while mice lacking Myoc showed enhanced muscle wasting. Furthermore, we identified the myocyte enhancer factor 2 C (MEF2C) transcription factor as a key upstream activator of Myoc whose gain of function significantly deterred cancer-induced muscle wasting and dysfunction in a preclinical model of pancreatic ductal adenocarcinoma (PDAC). Finally, compared with noncancer control patients, MYOC was significantly reduced in skeletal muscle of patients with PDAC defined as cachectic and correlated with MEF2c. These data therefore identify disruptions in MEF2c-dependent transcription of Myoc as a novel mechanism of cancer-associated muscle wasting that is similarly disrupted in muscle of patients with cachectic cancer. SIGNIFICANCE: This work identifies a novel transcriptional mechanism that mediates skeletal muscle wasting in murine models of cancer cachexia that is disrupted in skeletal muscle of patients with cancer exhibiting cachexia.